Accenture Helping Astellas Pharma Create Next-Generation Cloud-Based IT Core Platform for Advanced Real-Time Decision Making

Rhea-AI Summary

Accenture (NYSE: ACN) has developed a cloud-based IT platform for Astellas Pharma to enhance its global operations management. The platform, based on SAP S/4HANA and hosted on Microsoft Azure, streamlines data across supply chain, HR, and finance into a single view. It aims to boost innovation through AI and analytics while optimizing business processes. With deployments in Japan, the Americas, and EMEA, Astellas plans to utilize this centralized data for better decision-making and operational efficiency. The initiative marks a significant step towards Astellas' vision of digital transformation and improved healthcare solutions.

Positive

• Launch of a centralized cloud-based platform for Astellas, enhancing operational efficiency.
• Utilization of advanced technologies like AI and analytics to optimize business processes.
• Deployment already initiated in multiple regions (Japan, Americas, EMEA).
• Integration of data from various departments into a single view, facilitating better decision-making.

Negative

• None.

New platform supports sustainable and innovative medical solutions through centralized data visualization across global operations

TOKYO--(BUSINESS WIRE)-- Accenture (NYSE: ACN) helped Astellas Pharma Inc. create a cloud-based core IT platform that serves as the foundation for an advanced, data-driven management model for the company’s global operations. The new platform has been rolled out in Japan, the Americas and EMEA, with plans for further deployments.

The flexibility of the cloud enables Astellas to rapidly incorporate new and emerging technologies, accommodate business expansions such as mergers and acquisitions, and quickly deploy business continuity plans.

Based on SAP S/4HANA^® and running on Microsoft Azure, the new platform will consolidate and integrate data from Astellas’ supply chain, human resources and purchasing and accounting operations into a single view. Previously, this data was spread across countries, locations and departments.

It also includes SAP^® SuccessFactors^® solutions, human capital management software, that rather than solely focusing on transactional HR processes is designed to enhance employee productivity and agility globally to drive innovation.

This represents a step forward for Astellas to build an “enterprise digital twin,” which can simulate, predict and model the dynamic functions of an entire organization to explore potential business opportunities and highlight potential risk factors. This will enable Astellas to visualize information in a centralized manner to enhance decision-making.

In parallel with the development and implementation of the new platform, Accenture is delivering business process services to strengthen the agility of Astellas' global-scale operations. The data gathered by the new IT platform and operations services will be combined with digital technologies, such as artificial intelligence, robotic process automation and analytics to streamline its enterprise processes. This should help Astellas optimize sales and administrative expenses; accelerate efforts to expand its research capabilities; and foster greater innovation —ultimately enabling the company to generate additional resources for drug discovery.

“We were able to move to a full-cloud platform with the help of Accenture, which has extensive experience in implementing core platforms for global operations,” said Shinya Suda, senior vice president and head of Information Systems at Astellas. “The success of the project was due to Accenture's ability to bring together a wide range of experts from around the world for a truly ‘one-team’ approach with Astellas. We can centralize data and make the best use of this technology to create a business platform that supports visualization and bold data-driven decision-making. In collaboration with Accenture and other internal and external partners, Astellas will continue to focus on creating innovations that contribute to the health of people around the world.”

Motoki Fujita, vice president and head of Global Business Services at Astellas, added, “The new platform will accelerate our Global Business Service efforts to integrate operations on a global scale. This will create an environment that contributes to the business by optimizing selling and administrative expenses and creating an environment that allows employees to focus on high value-added work. We will leverage AI, RPA, and other digital technologies to thoroughly visualize and automate operations, and drive toward the goal of Intelligent Operation.”

Mitsuru Nagata, Senior Managing Director and Intelligent Platform Services lead for Accenture Technology in Japan, said, “I am pleased to be able to support this significant project that will accelerate the ‘One Astellas’ vision. By bringing together the talent of both companies from around the world and thanks to the strong commitment of Astellas' top management to complete the project we were able to set up this core platform. Accenture will continue to support Astellas' innovation efforts by leveraging our deep knowledge of the life sciences industry and our global network.”

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 674,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at accenture.com.

Accenture’s Life Sciences industry group helps pharmaceutical, biotech, medical technology. distributor and consumer health companies combine the latest technology with scientific breakthroughs to revolutionize how medical treatments are discovered, developed and delivered to patients around the world. To learn more, visit https://www.accenture.com/us-en/industries/life-sciences-index.

This content is provided for general information purposes and is not intended to be used in place of consultation with our professional advisors. This document refers to marks owned by third parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement or approval of this content by the owners of such marks is intended, expressed or implied.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

Copyright © 2022 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005756/en/

Ken Kanda

Accenture

+81 80 3723 9580

kentaro.kanda@accenture.com

Source: Accenture

FAQ

What is the purpose of the new platform developed by Accenture for Astellas Pharma?

The platform aims to enhance Astellas Pharma's global operations management by centralizing data and improving decision-making through advanced technologies.

What technologies are utilized in the new Astellas platform?

The platform is based on SAP S/4HANA and runs on Microsoft Azure, incorporating AI, robotic process automation, and analytics.

When was the new platform launched for Astellas Pharma?

The new platform has been rolled out recently across Japan, the Americas, and EMEA.

How will the new platform impact Astellas Pharma's operations?

It is expected to streamline processes, optimize costs, and foster innovation in drug discovery.

What is the stock symbol for Accenture?

The stock symbol for Accenture is ACN.